Changeflow GovPing Healthcare & Life Sciences Engineered Trimeric CD70 Proteins and Uses Ther...
Routine Notice Added Consultation

Engineered Trimeric CD70 Proteins and Uses Thereof, Fred Hutchinson Cancer Center, EP4041410A2

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

European Patent application EP4041410A2 filed by Fred Hutchinson Cancer Center for engineered trimeric CD70 proteins and uses thereof, published April 15, 2026. The application covers engineered trimeric CD70 proteins with therapeutic applications including anticancer uses, classified under IPC A61P 35/00 and C07K 16/40. The application designates 31 European Patent Convention contracting states for potential patent protection.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 22 changes logged to date.

What changed

European Patent application EP4041410A2 filed by Fred Hutchinson Cancer Center was published by the EPO on April 15, 2026, covering engineered trimeric CD70 proteins and their therapeutic uses.

For biotechnology and pharmaceutical entities working with CD70 targeting technologies, this publication constitutes prior art and may affect freedom-to-operate assessments. Competitors developing similar immunotherapy approaches should monitor the prosecution of this application across designated EPC states.

Archived snapshot

Apr 22, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

ENGINEERED TRIMERIC CD70 PROTEINS AND USES THEREOF

Publication EP4041410A2 Kind: A2 Apr 15, 2026

Applicants

Fred Hutchinson Cancer Center

Inventors

JAEGER, Carla, A., CORRENTI, Colin, E., RIDDELL, Stanley, R.

IPC Classifications

A61P 35/00 20060101AFI20231102BHEP C07K 16/40 20060101ALI20231102BHEP C12N 15/62 20060101ALI20231102BHEP C07K 16/46 20060101ALI20231102BHEP C07K 14/54 20060101ALI20231102BHEP A61P 31/00 20060101ALI20231102BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Notice
Branch
International
Legal weight
Non-binding
Stage
Consultation
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Biotechnology companies Research institutions
Industry sector
3254.1 Biotechnology
Activity scope
Patent application filing Biotechnology research Immunotherapy development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
3254.1 - Biotechnology 3254 - Pharmaceutical Manufacturing

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!